Kenneth DiPietro - Dec 22, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Human Resources Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 22, 2023
Transactions value $
-$303,608
Form type
4
Date filed
12/27/2023, 04:15 PM
Previous filing
Dec 21, 2023
Next filing
Jan 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $28K +8K +32.44% $3.50* 32.7K Dec 22, 2023 Direct
transaction CERE Common Stock Sale -$332K -8K -24.49% $41.45 24.7K Dec 22, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -8K -2.58% $0.00 302K Dec 22, 2023 Common Stock 8K $3.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.45 to $41.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option is fully vested and exercisable.